Loading…
Loading…
the competition is growing very rapidly. And it looks like it's inevitable. It will make an important impact on SKYRIZI
it sounds like IRA discounts are deeper this year than last year. You said it will not impact the long-term outlook, but will it impact the outlook in 2026
why is this economic uncertainty different than in the past? This one seems to be lingering longer than in past soft periods
Where does AbbVie stand in its analysis of the future of emraclidine? For instance, has a path forward become more clear in the last few months
The guidance for aesthetics was previously greater than $9 billion in 2030. What is that number now
the guidance had been a three percentage point headwind. It was just set on the call four percentage points. A year ago, it was two percentage points
Are there scenarios where these incremental sales can be delivered without orforglipron being a $5 billion product in 2026
has the TRAILBLAZER-ALZ 3 interim already been taken? The initiation of remternetug in the same setting would not seem the best sign for donanemab in Alzheimer's prevention
With what is widely viewed as disappointing orforglipron data, it seems injectables are where it's at for the foreseeable future
Lilly used aggressive formulary positioning as a lever with touts against other IL-17 competitors and, therefore, reduce choice
can you state that there has not been any conversations within Lilly questioning whether we are all significantly over our skis on this market
is this what we should expect from Merck going forward? A company that grows modestly in good times
Regarding GARDASIL growth slowdown globally, which seems to be a new disclosure, what new information emerged
In the VSPRS three data, did the placebo arm gain weight or lose weight
Is Pfizer's determination to persist underpinned by substantial confidentiality data -- confidential data or simply the desire to be a player in obesity
What does the drug pricing deal with Trump allow Pfizer to do that other companies will not be able to do other than, of course, AstraZeneca
I'm just wondering whether you would walk that number down?
do you think MFN legislation is only the most remote of possibilities or even simply not going to happen?
what is the percent utilization of the US plants?
can you share with us two or three things in the Pfizer R&D portfolio or system that you think need to be fixed?
What is the range of possible outcomes? And is dropping this version of the compound a possibility?